New pill combo shows promise against hepatitis c in Mid-Stage trial

NCT ID NCT05904470

Completed Disease control Sponsor: Atea Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times

Summary

This study tested a combination of two oral drugs, bemnifosbuvir and ruzasvir, in 275 adults with chronic hepatitis C. The main goal was to see if the treatment could clear the virus from the blood 12 weeks after finishing therapy. The trial was open-label, meaning everyone knew what they were taking, and it included people with and without cirrhosis.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Atea Study Site

San Antonio, Texas, 78215, United States
Atea Study Site

Manaus, Amazonas, 69040-000, Brazil
Atea Study Site

Salvador, Estado de Bahia, 41920-900, Brazil
Atea Study Site

Brasília, Federal District, 70200-730, Brazil
Atea Study Site

Rio de Janeiro, Rio Do Janeiro, 04037-030, Brazil
Atea Study Site

Porto Alegre, Rio Grande do Sul, 90035-074, Brazil
Atea Study Site

Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
Atea Study Site

Porto Velho, Rondônia, 78918-791, Brazil
Atea Study Site

Boa Vista, Roraima, 69304-015, Brazil
Atea Study Site

Botucatu, São Paulo, 18618-970, Brazil
Atea Study Site

Ijuí, São Paulo, 98700-000, Brazil
Atea Study Site

São José do Rio Preto, São Paulo, 15090-000, Brazil
Atea Study Site

São Paulo, São Paulo, 04119-001, Brazil
Atea Study Site

São Paulo, São Paulo, 05403-000, Brazil
Atea Study Site

Sorocaba, São Paulo, 18052-210, Brazil
Atea Study Site

Vancouver, British Columbia, V6Z 2C7, Canada
Atea Study Site

Toronto, Ontario, M5G 2C4, Canada
Atea Study Site

Rajkot, Gujarat, 360005, India
Atea Study Site

Surat, Gujarat, 395002, India
Atea Study Site

Belagavi, Karnataka, 590010, India
Atea Study Site

Nagpur, Maharashtra, 440010, India
Atea Study Site

Kolkata, West Bengal, 700020, India
Atea Study Site

Quatre Bornes, 72218, Mauritius
Atea Study Site

Chisinau, 2025, Moldova
Atea Study Site

Karachi, 74800, Pakistan
Atea Study Site

Karachi, 75600, Pakistan
Atea Study Site

Baguio City, 35100, Philippines
Atea Study Site

Iloilo City, 5000, Philippines
Atea Study Site

Mabalacat, 2023, Philippines
Atea Study Site

Bucharest, BUC, 022328, Romania
Atea Study Site

Bucharest, BUC, 30303, Romania
Atea Study Site

Constanța, CON, 900709, Romania
Atea Study Site

Craiova, DOL, 200073, Romania
Atea Study Site

Bucharest, 21105, Romania
Atea Study Site

Bloemfontein, Free State, 9301, South Africa
Atea Study Site

Johannesburg, Gauteng, 2193, South Africa
Atea Study Site

Randburg, Gauteng, 2087, South Africa
Atea Study Site

Somerset West, Western Cap, 7130, South Africa
Atea Study Site

Seoul, Gyeonggi-do, 120-752, South Korea
Atea Study Site

Yangsan, Gyeongsangnam, 626-770, South Korea
Atea Study Site

Busan, 47392, South Korea
Atea Study Site

Busan, 49241, South Korea
Atea Study Site

Seoul, 5505, South Korea
Atea Study Site

Seoul, 6351, South Korea
Atea Study Site

Adana, 1130, Turkey (Türkiye)
Atea Study Site

Ankara, 6100, Turkey (Türkiye)
Atea Study Site

Ankara, 6230, Turkey (Türkiye)
Atea Study Site

Ankara, 6800, Turkey (Türkiye)
Atea Study Site

Denizli, 20070, Turkey (Türkiye)
Atea Study Site

Izmir, 35100, Turkey (Türkiye)
Atea Study Site

Kayseri, 38010, Turkey (Türkiye)

Conditions

Explore the condition pages connected to this study.

CHRONIC HEPATITIS C VIRUS HCV HEPATIC CIRRHOSIS HEPATITIS C HEPATITIS C, CHRONIC